415 related articles for article (PubMed ID: 26875664)
21. Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
Park HY; Kang YM; Kang Y; Park TS; Ryu YK; Hwang JH; Kim YH; Chung BH; Nam KH; Kim MR; Lee CH; Han PL; Kim KS
J Neurosci; 2014 Aug; 34(35):11744-53. PubMed ID: 25164669
[TBL] [Abstract][Full Text] [Related]
22. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Solís O; García-Montes JR; Garcia-Sanz P; Herranz AS; Asensio MJ; Kang G; Hiroi N; Moratalla R
Neurobiol Dis; 2017 Jun; 102():133-139. PubMed ID: 28315782
[TBL] [Abstract][Full Text] [Related]
23. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
24. L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Rangel-Barajas C; Silva I; Lopéz-Santiago LM; Aceves J; Erlij D; Florán B
Neurobiol Dis; 2011 Jan; 41(1):51-61. PubMed ID: 20736067
[TBL] [Abstract][Full Text] [Related]
25. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
26. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
[TBL] [Abstract][Full Text] [Related]
27. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
[TBL] [Abstract][Full Text] [Related]
28. Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Gangarossa G; Guzman M; Prado VF; Prado MA; Daumas S; El Mestikawy S; Valjent E
Neurobiol Dis; 2016 Mar; 87():69-79. PubMed ID: 26711621
[TBL] [Abstract][Full Text] [Related]
29. Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Ferrari DP; Bortolanza M; Del Bel EA
Neurotox Res; 2021 Jun; 39(3):705-719. PubMed ID: 33687725
[TBL] [Abstract][Full Text] [Related]
30. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
31. Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Ryu YK; Park HY; Go J; Kim YH; Hwang JH; Choi DH; Noh JR; Rhee M; Han PL; Lee CH; Kim KS
J Neural Transm (Vienna); 2018 Sep; 125(9):1319-1331. PubMed ID: 29998409
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Xie CL; Lin JY; Wang MH; Zhang Y; Zhang SF; Wang XJ; Liu ZG
Sci Rep; 2016 Mar; 6():23527. PubMed ID: 26997328
[TBL] [Abstract][Full Text] [Related]
33. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Chotibut T; Fields V; Salvatore MF
Mol Pharmacol; 2014 Dec; 86(6):675-85. PubMed ID: 25208966
[TBL] [Abstract][Full Text] [Related]
34. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
Lebel M; Chagniel L; Bureau G; Cyr M
Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
[TBL] [Abstract][Full Text] [Related]
35. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
36. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
[TBL] [Abstract][Full Text] [Related]
37. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
[TBL] [Abstract][Full Text] [Related]
38. L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Wang R; Shao M
Ann Palliat Med; 2020 May; 9(3):947-956. PubMed ID: 32279520
[TBL] [Abstract][Full Text] [Related]
39. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
[TBL] [Abstract][Full Text] [Related]
40. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
